The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
Open accessAbstract
Summary Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe dengue by promoting heterotypic virus entry via Fcγ receptors (FcγR). We immortalized memory B cells from individuals after primary or secondary infection and analyzed anti-DENV monoclonal antibodies (mAbs) thus generated. MAbs to envelope (E) protein domain III (DIII) were either serotype specific or cross-reactive and potently neutralized DENV infection. DI/DII- or viral membrane protein prM-reactive mAbs neutralized poorly and showed broad cross-reactivity with the four DENV serotypes. All mAbs enhanced infection at subneutralizing concentrations. Three mAbs targeting distinct epitopes on the four DENV serotypes and engineered to prevent FcγR binding did not enhance infection and neutralized DENV in vitro and in vivo as postexposure therapy in a mouse model of lethal DENV infection. Our findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution
Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C., & Harrison, S. C. (1995) · Nature · doi:10.1038/375291a0 · Cited by 1,437
Self-citationTiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., & Wardemann, H. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.09.017 · Cited by 1,107
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., et al. (2010) · Science · doi:10.1126/science.1185181 · Cited by 943
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Gibbons, R. V., & Vaughn, D. W. (2002) · BMJ · doi:10.1136/bmj.324.7353.1563 · Cited by 783
Neutralization and Antibody-Dependent Enhancement of Dengue Viruses
Halstead, S. B. (2003) · Advances in Virus Research · doi:10.1016/s0065-3527(03)60011-4 · Cited by 739
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
Self-citationProspects for a dengue virus vaccine
Whitehead, S. S., Blaney, J. E., Durbin, A. P., & Murphy, B. R. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1690 · Cited by 623
Self-citationKliks, S. C., Nimmanitya, S., Nisalak, A., & Burke, D. S. (1988) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1988.38.411 · Cited by 578
Proteolytic activation of tick-borne encephalitis virus by furin
Stadler, K., Allison, S. L., Schalich, J., & Heinz, F. X. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8475-8481.1997 · Cited by 561
Cited by
Dengue: a continuing global threat
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., et al. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2460 · Cited by 2,082
Self-citationAntibody-dependent enhancement of severe dengue disease in humans
Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G., Gordon, A., Balmaseda, A., & Harris, E. (2017) · Science · doi:10.1126/science.aan6836 · Cited by 1,205
Self-citationModified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationBeyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms
Rothman, A. L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3014 · Cited by 770
Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection
Stettler, K., Beltramello, M., Espinosa, D. A., Graham, V., Cassotta, A., Bianchi, S., Vanzetta, F., Minola, A., Jaconi, S., Mele, F., et al. (2016) · Science · doi:10.1126/science.aaf8505 · Cited by 758
Self-citationThe promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
From Vaccines to Memory and Back
Sallusto, F., Lanzavecchia, A., Araki, K., & Ahmed, R. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.008 · Cited by 637
Self-citationHuman antibody responses after dengue virus infection are highly cross-reactive to Zika virus
Priyamvada, L., Quicke, K. M., Hudson, W. H., Onlamoon, N., Sewatanon, J., Edupuganti, S., Pattanapanyasat, K., Chokephaibulkit, K., Mulligan, M. J., Wilson, P. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607931113 · Cited by 587
Structural basis of potent Zika–dengue virus antibody cross-neutralization
Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., Simon-Lorière, E., Sakuntabhai, A., Cao-Lormeau, V.-M., Haouz, A., et al. (2016) · Nature · doi:10.1038/nature18938 · Cited by 533
Self-citationDai, L., Song, J., Lu, X., Deng, Y.-Q., Musyoki, A. M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.04.013 · Cited by 502
Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. H., Duangchinda, T., et al. (2015) · Nature Immunology · doi:10.1038/ni.3058 · Cited by 500
Self-citationA perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Self-citationReverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 435
New insights into the immunopathology and control of dengue virus infection
Screaton, G., Mongkolsapaya, J., Yacoub, S., & Roberts, C. (2015) · Nature Reviews Immunology · doi:10.1038/nri3916 · Cited by 394
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
de Alwis, R., Smith, S. A., Olivarez, N. P., Messer, W. B., Huynh, J. P., Wahala, W. M. P. B., White, L. J., Diamond, M. S., Baric, R. S., Crowe, J. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200566109 · Cited by 390
Self-citationStructural Basis of Zika Virus-Specific Antibody Protection
Zhao, H., Fernandez, E., Dowd, K. A., Speer, S. D., Platt, D. J., Gorman, M. J., Govero, J., Nelson, C. A., Pierson, T. C., Diamond, M. S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.020 · Cited by 375
Self-citationThe Human Antibody Response to Dengue Virus Infection
Wahala, W. M. P. B., & De Silva, A. M. (2011) · Viruses · doi:10.3390/v3122374 · Cited by 354
Self-citationReceptors and routes of dengue virus entry into the host cells
Cruz-Oliveira, C., Freire, J. M., Conceição, T. M., Higa, L. M., Castanho, M. A. R. B., & Da Poian, A. T. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuu004 · Cited by 338
Dengue Antibody-Dependent Enhancement: Knowns and Unknowns
Halstead, S. B. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0022-2014 · Cited by 336
Flavivirus Entry Receptors: An Update
Perera-Lecoin, M., Meertens, L., Carnec, X., & Amara, A. (2013) · Viruses · doi:10.3390/v6010069 · Cited by 323
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Degrees of maturity: the complex structure and biology of flaviviruses
Pierson, T. C., & Diamond, M. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.02.011 · Cited by 265
Self-citationThe bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design
Rey, F. A., Stiasny, K., Vaney, M., Dellarole, M., & Heinz, F. X. (2018) · EMBO reports · doi:10.15252/embr.201745302 · Cited by 259
Self-citationRapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in Humans
Wrammert, J., Onlamoon, N., Akondy, R. S., Perng, G. C., Polsrila, K., Chandele, A., Kwissa, M., Pulendran, B., Wilson, P. C., Wittawatmongkol, O., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06075-11 · Cited by 257
Fc receptors in antibody‐dependent enhancement of viral infections
Taylor, A., Foo, S., Bruzzone, R., Vu Dinh, L., King, N. J. C., & Mahalingam, S. (2015) · Immunological Reviews · doi:10.1111/imr.12367 · Cited by 255
Kwissa, M., Nakaya, H. I., Onlamoon, N., Wrammert, J., Villinger, F., Perng, G. C., Yoksan, S., Pattanapanyasat, K., Chokephaibulkit, K., Ahmed, R., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.06.001 · Cited by 254
The role and function of Fcγ receptors on myeloid cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138
A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus
Ku, M. W., Anna, F., Souque, P., Petres, S., Prot, M., Simon-Loriere, E., Charneau, P., & Bourgine, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.016 · Cited by 29
Zlatkovic, J., Tsouchnikas, G., Jarmer, J., Koessl, C., Stiasny, K., & Heinz, F. X. (2013) · Journal of Virology · doi:10.1128/jvi.01690-13 · Cited by 23
Salem, G. M., Galula, J. U., Wu, S.-R., Liu, J.-H., Chen, Y.-H., Wang, W.-H., Wang, S.-F., Song, C.-S., Chen, F.-C., Abarientos, A. B., et al. (2024) · Communications Biology · doi:10.1038/s42003-023-05661-w · Cited by 14
Metadata
- Authors
- Beltramello, M., Williams, K. L., Simmons, C. P., Macagno, A., Simonelli, L., Quyen, N. T. H., Sukupolvi-Petty, S., Navarro-Sanchez, E., Young, P. R., de Silva, A. M., Rey, F. A., Varani, L., Whitehead, S. S., Diamond, M. S., Harris, E., Lanzavecchia, A., & Sallusto, F.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 8
- Issue
- 3
- Pages
- 271-283
- ISSN
- 1931-3128 (ISSN-L)
- OpenAlex
- W2051298245
- Cited by
- 592
- References
- 52
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.